

Quick Facts on Regenerative Medicine & CCRM



CCRM

Centre for Commercialization of **Regenerative** Medicine

Regenerative Medicine (RM) harnesses the power of stem cells, tissue engineering, and biomaterials, to repair, regenerate or replace diseased cells, tissue and organs. It has the potential to treat, manage and perhaps cure some of the most debilitating and costly diseases in the world today such as heart disease and diabetes.

The Industry

- The current global market for RM is USD\$3.6B and conservative estimates suggest that it will exceed USD\$11B within the coming decade and its annual growth is projected at 30%¹
- More than 150 stem cell and regenerative medicine licensing deals were concluded during 2009/10²
- The U.S. National Institutes of Health is tracking over 900 clinical trials involving adult stem cells for therapeutic applications such as heart disease, diabetes, bone regrowth, vision impairments and severe burns¹
- There is increased intensity of regenerative medicine industry activity
 - [Shire acquires Advanced BioHealing for \\$750 million](#) in May 2011
 - [Dendreon receives FDA approval for expansion of Provenge®](#) for treatment of men with advanced prostate cancer in March 2011; projected 2011 revenue of \$350-400 million
 - [Cephalon buys 20% stake in Mesoblast for \\$130 million](#) upfront and \$1.7 billion in milestone payments in December 2010
- Canada ranks 1st in cost competitiveness for biomedical R&D compared to other industrialized nations¹

CCRM's Scientific Strengths

- The Ontario Stem Cell Initiative is a network of 65 scientists³
- The University of Toronto ranks 2nd in the world and Mount Sinai ranked 4th in terms of scientific stem cell publications¹
- Six of the leading 20 biomaterials researchers in North America are located in Ontario⁴
- CCRM's six founding institutions represents a substantial portion of Ontario's investment in RM's activity in Ontario⁵
 - Hospital for Sick Children
 - McMaster University
 - Mount Sinai Hospital
 - Ottawa Hospital Research Institute
 - University Health Network
 - University of Toronto

CCRM's Commercialization Strengths

- More than 55 licenses have been executed based on the work of CCRM researchers
- CCRM researchers have founded more than 12 companies in the past 10 years, employing more than 100 highly qualified personnel
- CCRM researchers have generated more than 140 filed or issued patents in the last 10 years

For more information on CCRM, please contact sandra.donaldson@ccrm.ca or 647-926-1228 or go to the CCRM website www.ccrm.ca.

¹MaRS Venture Group Regenerative Medicine Industry Report, 2009

²Medtrack deal search conducted by MaRSDD, June 2010

³The Ontario Stem Cell Initiative, May 23, 2011

⁴Regenerative Medicine Asset Map, MaRSDD, 2008